146 related articles for article (PubMed ID: 26850971)
1. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer. Eur Urol 2015;68:167-8.
Greco M; Butticè S; Magno C; Onida S
Eur Urol; 2016 Aug; 70(2):e51-2. PubMed ID: 26850971
[No Abstract] [Full Text] [Related]
2. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
Sharma P; Sawar A; Spiess P
Eur Urol; 2015 Oct; 68(4):e79-80. PubMed ID: 26007640
[No Abstract] [Full Text] [Related]
3. Reply to Pranav Sharma, Asad Sawar and Philippe Spiess' letter to the editor re: re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
Rogers CG; Barod R; Schwartz S; Menon M
Eur Urol; 2015 Oct; 68(4):e81. PubMed ID: 26004799
[No Abstract] [Full Text] [Related]
4. Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer.
Rogers C; Barod R; Schwartz S; Menon M
Eur Urol; 2015 Jul; 68(1):167-8. PubMed ID: 25843640
[No Abstract] [Full Text] [Related]
5. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
6. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
Mollica V; Rizzo A; Massari F
Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
[No Abstract] [Full Text] [Related]
7. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
8. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.
Nunez Bragayrac L; Hoffmeyer J; Abbotoy D; Attwood K; Kauffman E; Spiess P; Wagner A; Schwaab T
World J Urol; 2016 Dec; 34(12):1651-1656. PubMed ID: 27084776
[TBL] [Abstract][Full Text] [Related]
9. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
Li J; Chen B; Cao D
Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
[No Abstract] [Full Text] [Related]
10. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
[TBL] [Abstract][Full Text] [Related]
11. Re: Ithaar H. Derweesh, Rana R. McKay, Aditya Bagrodia. Primary Cytoreductive Nephrectomy: Standing the Test of Time? Eur Urol. 2023;83:152-3.
Mejean A
Eur Urol; 2023 May; 83(5):e135. PubMed ID: 36781338
[No Abstract] [Full Text] [Related]
12. Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy.
Williams T; Rodriguez R; Murray K; Kovaleski A; Madan R; Van Veldhuizen P
Urology; 2015 Feb; 85(2):283-7. PubMed ID: 25623665
[No Abstract] [Full Text] [Related]
13. Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma.
Agarwal N; Shuch B; Pal SK
JAMA Oncol; 2016 Oct; 2(10):1273-1274. PubMed ID: 27254305
[No Abstract] [Full Text] [Related]
14. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
[No Abstract] [Full Text] [Related]
15. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
Ghoreifi A; Djaladat H
Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
[No Abstract] [Full Text] [Related]
16. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma.
Karam JA; Babaian KN; Tannir NM; Matin SF; Wood CG
Minerva Urol Nefrol; 2015 Jun; 67(2):149-56. PubMed ID: 25645343
[TBL] [Abstract][Full Text] [Related]
17. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016.
Bex A; Ljungberg B; van Poppel H; Powles T;
Eur Urol; 2016 Dec; 70(6):901-905. PubMed ID: 27445002
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
19. Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?
Molina AM; Hu J; Nanus DM
J Clin Oncol; 2016 Sep; 34(27):3235-6. PubMed ID: 27528717
[No Abstract] [Full Text] [Related]
20. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
